Home  »  Companies   »  Here’s Our Rant About Allogene Therapeutics ...

Here’s Our Rant About Allogene Therapeutics Inc. (ALLO)

Allogene Therapeutics Inc. (NASDAQ:ALLO) went up by 1.74% from its latest closing price compared to the recent 1-year high of $27.86. The company’s stock price has collected -2.34% of loss in the last five trading sessions.

Is It Worth Investing in Allogene Therapeutics Inc. (NASDAQ :ALLO) Right Now?

Plus, the 36-month beta value for ALLO is at 0.43.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


ALLO currently public float of 80.09M and currently shorts hold a 25.16% ratio of that float. Today, the average trading volume of ALLO was 2.10M shares.

ALLO’s Market Performance

ALLO stocks went down by -2.34% for the week, with a monthly jump of 46.00% and a quarterly performance of 16.33%, while its annual performance rate touched -53.63%. The volatility ratio for the week stands at 6.96% while the volatility levels for the past 30 days are set at 9.18% for Allogene Therapeutics Inc. The simple moving average for the period of the last 20 days is 17.23% for ALLO stocks with a simple moving average of -12.13% for the last 200 days.

Analysts’ Opinion of ALLO

Many brokerage firms have already submitted their reports for ALLO stocks, with Robert W. Baird repeating the rating for ALLO by listing it as a “Neutral.” The predicted price for ALLO in the upcoming period, according to Robert W. Baird is $11 based on the research report published on June 03rd of the current year 2022.

B. Riley Securities, on the other hand, stated in their research note that they expect to see ALLO reach a price target of $21, previously predicting the price at $30. The rating they have provided for ALLO stocks is “Buy” according to the report published on February 28th, 2022.

ALLO Trading at 33.65% from the 50-Day Moving Average

After a stumble in the market that brought ALLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.08% of loss for the given period.

Volatility was left at 9.18%, however, over the last 30 days, the volatility rate increased by 6.96%, as shares surge +47.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +49.94% upper at present.

During the last 5 trading sessions, ALLO fell by -2.34%, which changed the moving average for the period of 200-days by -52.85% in comparison to the 20-day moving average, which settled at $10.15. In addition, Allogene Therapeutics Inc. saw -21.72% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ALLO starting from WITTE OWEN N., who sale 10,000 shares at the price of $11.76 back on Jun 22. After this action, WITTE OWEN N. now owns 233,271 shares of Allogene Therapeutics Inc., valued at $117,600 using the latest closing price.

Amado Rafael, the EVP of R&D and CMO of Allogene Therapeutics Inc., sale 2,000 shares at $11.18 during a trade that took place back on Jun 21, which means that Amado Rafael is holding 544,257 shares at $22,360 based on the most recent closing price.

Stock Fundamentals for ALLO

Equity return is now at value -32.30, with -28.90 for asset returns.